Navigation Links
Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009

SAN DIEGO, Oct. 26 /PRNewswire/ -- Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

The Company's flu program has identified a compound, IkT-041, comparable in activity to viral neuraminidase inhibitors (e.g. Tamiflu, Relenza), but one that is far less likely to stimulate resistance. IkT-041 has excellent human dosing metrics (up to 3000 mg/day), outstanding safety history in humans and an oral bioavailability > 70%.

The Company's orphan drug program is focused on satisfying an unmet medical need for the treatment of polyomavirus infections. The human polyomaviruses, JC and BK, are responsible for fatal disorders of the brain and kidney, to include progressive multifocal leukoencephalopathy (PML), an AIDS-defining disease that also afflicts patients on autoimmune disorder treatments for MS, lupus and arthritis. IkT-001 has a mechanism of action that can suppress polyomavirus reactivation in viral reservoirs, even in patients who are immune compromised. In some cases, a therapeutic vaccine effect can be realized with this product.

The Company is on track to file 3 Initial New Drug applications in 2010 or early 2011 and enter late stage clinical trials shortly thereafter. First product launch is slated for 2013, addressing a total market of greater than 100 million patients with annual revenue potential of at least $2.3 billion.

SOURCE Inhibikase Therapeutics

SOURCE Inhibikase Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual BIO Investor Forum
2. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
3. Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting
4. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
5. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
6. ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease
7. Prime Therapeutics Receives 2010 TIPPS Certification for Adherence to High Transparency Standards
8. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
9. Solace Therapeutics, Inc. Announces CE Mark Approval
10. Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference
11. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
Post Your Comments:
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
Breaking Medicine News(10 mins):